Activated autologous blood component therapy (AABCT)
Activated autologous blood component therapy (AABCT) is becoming a more sophisticated concept than simply “PRP.” The current direction is toward patient-specific, activated blood-derived biologics that deliver platelets, fibrin, leukocytes, plasma proteins and growth factors in a controlled way.
One important point first: “Activated autologous blood component therapy” is not yet a universally standardized medical term. In the literature, closely related approaches are generally described as PRP, activated PRP/platelet gel, platelet-rich fibrin (PRF), autologous platelet concentrate, platelet-fibrin plasma, or autologous blood-derived products.
What is new and exciting?
1. The field is moving from “platelet concentration” to “platelet dose + biologic composition.”
The old PRP question was:
“How many platelets are in the preparation?”
The newer question is:
“What exact cellular and molecular payload are we delivering to the wound, and for how long?”
Recent expert consensus emphasizes that platelet concentration alone may be insufficient; the total platelet dose, leukocyte content, activation method, fibrin characteristics and delivery method all potentially influence outcomes.
2. Activation is becoming a major therapeutic variable
Activation causes platelet degranulation and release of numerous biologically active molecules—including PDGF, VEGF, EGF, TGF-β and IGF-related factors—that participate in angiogenesis, fibroblast activity, extracellular-matrix formation and tissue repair.
Common activation strategies include:
- Calcium chloride/calcium gluconate
- Thrombin
- Calcium + thrombin
- Collagen
- Endogenous activation, particularly with PRF-type preparations
The important emerging issue is kinetics. Thrombin can produce rapid platelet activation and gel formation, whereas other approaches may provide a more prolonged release of bioactive molecules.
3. The “next generation” is moving toward fibrin-based systems
This is particularly interesting for advanced wound care.
Instead of simply injecting liquid PRP, researchers are developing preparations that create a fibrin matrix/scaffold capable of retaining platelets and bioactive molecules at the wound.
A 2024 study of platelet fibrin plasma (PFP) reported >90% four-week healing in a cohort of postoperative refractory wounds and demonstrated increased vascularization and granulation tissue formation. However, the authors appropriately note that more research is needed before PFP can be considered a substitute for PRP in difficult wounds such as diabetic foot ulcers.
4. An especially interesting 2025 finding: liquid may outperform gel in some circumstances
A recent comparative study examined liquid versus gel PRP and found that liquid preparations released platelet-derived effectors more effectively over seven days and produced stronger effects on cellular proliferation and migration than the gel preparations tested.
That’s important because it challenges the intuitive assumption that:
“More fibrin/gel = better wound healing.”
The optimal formulation may instead depend on whether the clinical objective is:
rapid hemostasis → scaffold → sustained growth-factor delivery → cellular stimulation → angiogenesis.
Where AABCT may become particularly powerful
For advanced wound care, I would divide the potential applications into:
| Application | Current potential |
|---|---|
| Diabetic foot ulcers | ⭐⭐⭐⭐ |
| Chronic postoperative wounds | ⭐⭐⭐⭐ |
| Venous leg ulcers | ⭐⭐⭐⭐ |
| Pressure injuries | ⭐⭐⭐ |
| Traumatic wounds | ⭐⭐⭐⭐ |
| Tendon/ligament repair | ⭐⭐⭐⭐ |
| Bone healing | ⭐⭐⭐ |
| Surgical wound optimization | ⭐⭐⭐⭐ |
| Complex limb-salvage wounds | ⭐⭐⭐⭐ |
| Cartilage/orthopedic regeneration | ⭐⭐⭐⭐ |
The evidence is strongest for adjunctive use, rather than replacing meticulous wound-bed preparation and standard advanced wound care.
For diabetic foot ulcers specifically, a recent expert consensus reviewing the literature found generally favorable results for PRP, including meta-analyses showing higher healing rates than conventional treatment. But it also highlighted a major problem: many studies don’t adequately report platelet dose, platelet concentration, activation status or exact treatment protocol, making studies difficult to compare.
The really important future direction
I think the most exciting evolution is:
“Personalized autologous blood-derived regenerative therapy.”
Instead of saying:
“Give the patient PRP.”
the future protocol becomes something like:
Patient → blood characterization → customized separation → customized platelet/leukocyte/fibrin composition → controlled activation → targeted delivery → biologic monitoring → repeat treatment according to wound response.
In other words, AABCT could eventually become a platform rather than a single treatment.
This is particularly relevant to your interest in advanced wound care and limb salvage, because a chronic diabetic wound is biologically very different from an acute surgical wound.
What I would consider the “latest and greatest” AABCT platform
If I were designing a modern regenerative-wound program in 2026, I would be interested in combining:
1. Autologous blood characterization
CBC/platelets ± relevant metabolic/inflammatory assessment.
2. Controlled platelet concentration
Rather than assuming “more platelets = better.”
3. Leukocyte optimization
Different wounds may theoretically benefit from different leukocyte profiles.
4. Controlled activation
Calcium/collagen/autologous thrombin rather than indiscriminate activation.
5. Fibrin architecture
Use the fibrin component as a biological scaffold where appropriate.
6. Liquid + matrix formulations
Potentially using liquid activated components for cellular signaling and fibrin-based components for structural coverage.
7. Image-guided/intralesional delivery
Particularly for undermining, tunneling or poorly vascularized wound margins.
8. Combination with advanced wound technologies
Debridement, off-loading, NPWT, oxygenation optimization, advanced dressings—and potentially modalities such as HILT.
9. Serial biologic assessment
Don’t simply repeat PRP every week; assess wound-area reduction, granulation, perfusion and infection status.
The major caveat
AABCT is promising, but it is not yet a standardized “regenerative cure.”
The biggest scientific problem remains heterogeneity. Two clinics can both say “activated PRP” while delivering substantially different platelet concentrations, leukocyte counts, activation methods, fibrin structures and doses.
That is why the field is increasingly moving toward standardization and characterization of the final product, rather than simply naming the therapy “PRP.”
My bottom line
For2026, I would put the field’s trajectory like this:
PRP → activated PRP → platelet gel → PRF → platelet-fibrin plasma → engineered/patient-specific autologous blood-derived biologic.
And for advanced wound care, the most interesting frontier is probably controlled activation + fibrin matrix + optimized platelet dose + precise wound delivery, rather than simply increasing the platelet concentration.
The future is here, now
Interested? See us.
ZP